Rx_2.26 (HemOnc) Flashcards
1
Q
Most common supratentorial tumor in children….
A
- craniopharyngioma <== Rathke’s pouch
- ==> H/A, BTH
- ==> deficiency of ant. pituitary hormones
- e.g. GH
- cystic tumor lined by stratified squamous and filled w/viscous yellow, cholesterol rich fluid
2
Q
Warfarin: MOA, toxocity
A
- MOA =
- inhibits vit K epoxide reducatase ==>
- inability to carboxylate factors II, VII, IX, X and proteins C & S
- Toxicity
- bleeding
- teratogenic
- skin/tissue necpsis
3
Q
Classic signs & sx of Hodgkin’s Lymphoma
A
- night sweats
- fever
- weight loss
- **presence of Reed-Sternberg cell

4
Q
Tx of Hodgkin’s lymphoma
A
-
ABVD regimen:
- Adriamycin (doxorubicin)
- Bleomycin
- Vinblastine
- Dacarbazine
5
Q
Vinblastine: MOA, SE
A
- MOA:
- inhibits MT formation of mitotic spindle
- SE:
- alopecia
- constipation
- myelosuppression
- neurotoxicity (rare)
6
Q
abnormal monoclonal immunoglobulin level + no other signs of malignancy ==> dx? tx?
A
- monoclonal gammopathy of undeterined significance (MGUS)
- tx = monitoring @ regular intervals for progression
7
Q
Cancer drugs that act in the M phase of the cell cycle
A
- vinca alkaloids=inhibit MT fxn/spindle formation
- vincristine
- vinblastine
- paclitaxel
- binds to tubulin and hyperstabilizes MTs that have already polymerized ==> prevents spindle breakdown
8
Q
5-fluorouracil: MOA, use
A
- anti-metabolite
- prevents formation of thymidine vua inhibition of thymidylate synthase
- use = cancer drug
9
Q
6-mercaptopurine: MOA, use
A
- anti-metabolite
- inhibits formation of purines
- use = cancer drug
10
Q
Methotrexate: MOA, use
A
- anti-metabolite
- inhibts dihydrofolate reductase ==> inhibition of DNA synthesis (via same pathway as 5-fluorouracil)
- use = cancer drug
11
Q
Busulfan: MOA, use
A
- DNA alkylating agent (cell cyle nonspecific)
- use = CML
12
Q
Bleomycin: MOA
A
- inhibit replication by inducing DNA strand breaks via free radical formation
- strand breakage interrupts G2 phase of cell cycle (after DNA synthesis)
13
Q
Cyclophosphamide: MOA
A
- DNA alkylating agent (cell cycle nonspecific)
14
Q
Hematologic consequences of colon cancer
A
- carcinoma of colon ==> chronic blood loss
- ==> iron deficiency anemia
- hypochromic, microcytic anemia
15
Q
Iron toxicity presentation & tx
A
- N/V + abdominal pain w/in 4 hours of ingestion
- tx = deferoxamine = chelating agent
- also tx for aluminum toxicity
16
Q
Deferoxamine: uses, SE
A
- use
- iron toxicity
- aluminum toxicity
- SE
- hypotensive shock 2o to histamine release
- allergic rxn
- (rare) neural/renal toxicity
17
Q
Dimercaprol use
A
- tx poisoning by arsenic, mercury, gold
18
Q
Penicillamine uses
A
- tx of lead and arsenic toxicity
- chelating agent in Wilson’s disease (disorder of copper metabolism)
19
Q
“WEPT”
A
-
Warfarin Extrinsic, PT
- Warfarin ==I extrinsic pathway
- TF + 7 => 10 + 5 => 2 => 1
- Monitor PT
- Warfarin ==I extrinsic pathway
20
Q
Characteristics of Ehrlichiosis
A
- cause = Ehrlichia chaffeensis
- carried by a tick on dogs/deer in Americas
- member of the order Rickettsia
- presentation
- fever, H/A malaise
- truncal rash
- blood = berry-like cytoplasmic inclusion in macs or PMNs
- tx
- doxycycline
21
Q
Histologic feature + possible causes?

A
- target cell
-
HALT:
- Hemoglobin C disease
- Asplenia
- Liver disease
- Thalassemia
22
Q
Presentation of thalassemias
A
- microcytic, hypochromic anemia
- alpha-thalassemia
- alpha globin chain is underproduced
- severity = ~#/4 genes mutated
- loss of all four alpha genes ==> hydrops fetalis
- beta-thalassemia
- beta globin chain underproduced
- major = absence
- minor = underproduction